Paricalcitol is a vitamin D2 analog indicated for the prevention and treatment of secondary hyperparathyroidism in patients 5 years of age and older with chronic kidney disease (CKD) on dialysis. MedsAcross supplies Paricalcitol for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
ZEMPLAR is indicated for the prevention and treatment of secondary hyperparathyroidism in patients 5 years of age and older with chronic kidney disease (CKD) on dialysis. ZEMPLAR is a vitamin D analog indicated for the prevention and treatment of secondary hyperparathyroidism in patients 5 years of age and older with chronic kidney disease on dialysis.
Source: US FDA prescribing information
Paricalcitol is a synthetic, biologically active vitamin D 2 analog. Preclinical and in vitro studies have demonstrated that paricalcitol's biological actions are mediated through binding of the vitamin D receptor (VDR), which results in the selective activation of vitamin D responsive pathways. Vitamin D and paricalcitol have been shown to reduce PTH levels by inhibiting PTH synthesis and secretion.
Source: US FDA prescribing information
Ensure serum calcium is not above the upper limit of normal before initiating. Administer ZEMPLAR intravenously through a hemodialysis vascular access at any time during dialysis. Adult Dose: Initiate at 0.04 mcg/kg to 0.1 mcg/kg (2.8 mcg to 7 mcg) no more frequently than every other day. Target maintenance dose to intact parathyroid hormone (PTH) levels within the desired therapeutic range and serum calcium within normal limits. Monitor serum calcium frequently (e.g., twice weekly) and intact PTH levels every 2 to 4 weeks after dose initiation or adjustment. See Table 1 in the full prescribing information for titration recommendations based upon intact PTH levels. Suspend or decrease the dose for persistent abnormally low intact PTH or serum calcium consistently above the normal range.
Source: US FDA prescribing information
ZEMPLAR is contraindicated in patients with: Hypercalcemia Vitamin D toxicity Known hypersensitivity to paricalcitol or any of the inactive ingredients in ZEMPLAR. Hypersensitivity adverse reactions have been reported [e.g., angioedema (including laryngeal edema) and urticaria]. Hypercalcemia. Vitamin D toxicity. Known hypersensitivity to paricalcitol or any inactive ingredient.
Source: US FDA prescribing information
Hypercalcemia: Can occur during treatment with ZEMPLAR and can lead to cardiac arrhythmias and seizures. Severe hypercalcemia may require emergency attention. The risk may be increased when ZEMPLAR is used concomitantly with high dose calcium preparations, thiazide diuretics, or vitamin D compounds. Inform patients about symptoms of hypercalcemia and monitor serum calcium prior to initiation and during treatment and adjust dose accordingly. Digitalis toxicity: Risk increases with hypercalcemia. In patients using digitalis compounds, monitor both serum calcium and patients for signs and symptoms of digitalis toxicity. Monitor more frequently when initiating or adjusting the dose of ZEMPLAR. Adynamic Bone Disease: May develop and increase risk of fractures if intact PTH levels are suppressed to abnormally low levels. Monitor intact PTH levels and adjust dose if needed.
Source: US FDA prescribing information
The following serious adverse reactions are described below and elsewhere in the labeling: Hypercalcemia Adynamic Bone Disease The most common adverse reactions (> 5% and more frequent than placebo) are nausea, vomiting and edema.
Source: US FDA prescribing information
Table 4 includes clinically significant drug interactions with ZEMPLAR. Table 4. Clinically Significant Drug Interactions with ZEMPLAR Drugs that May Increase the risk of Hypercalcemia Clinical Impact Concomitant administration of high doses of calcium-containing preparations or other vitamin D compounds may increase the risk of hypercalcemia. Thiazide diuretics are known to induce hypercalcemia by reducing excretion of calcium in the urine. Examples Calcium-containing products, other vitamin D compounds or thiazide diuretics Intervention Monitor calcium more frequently and adjust ZEMPLAR dose as needed. Digitalis Compounds Clinical Impact ZEMPLAR can cause hypercalcemia which can potentiate the risk of digitalis toxicity.
Source: US FDA prescribing information
Store at 25°C (77°F). Excursions permitted between 15° to 30°C (59° to 86°F). The contents of the multiple-dose vial remain stable up to seven days after initial use when stored at controlled room temperature.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
11 presentations of Paricalcitol, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Paricalcitol 1 mcg capsuleOralGeneric name | — | US FDA | Available on request |
| Paricalcitol 2 mcg capsuleOralGeneric name | — | US FDA | Available on request |
| Paricalcitol 4 mcg capsuleOralGeneric name | — | US FDA | Available on request |
| Paricalcitol 10 mcg/2 mL injectionIntravenousGeneric name | — | US FDA | Available on request |
| Paricalcitol 2 mcg/1 mL injectionIntravenousGeneric name | — | US FDA | Available on request |
| Paricalcitol 5 mcg/1 mL injectionIntravenousGeneric name | — | US FDA | Available on request |
| Zemplar 1 mcg capsuleOral | AbbVie | US FDA | Available on request |
| Zemplar 10 mcg/2 mL injectionIntravenous | AbbVie | US FDA | Available on request |
| Zemplar 2 mcg capsuleOral | AbbVie | US FDA | Available on request |
| Zemplar 2 mcg/1 mL injectionIntravenous | AbbVie | US FDA | Available on request |
| Zemplar 5 mcg/1 mL injectionIntravenous | AbbVie | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 17 April 1998 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Conditions linked to Paricalcitol in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 11 presentations of Paricalcitol and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Paricalcitol, including Zemplar.
Yes. The US FDA first approved Paricalcitol on 17 April 1998, according to Drugs@FDA.
No listed presentation of Paricalcitol is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Paricalcitol is classified under ATC code H05BX02 (Paricalcitol).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.